Lymphoma

Travel Insurance for Lymphoma Patients

Lymphoma encompasses a wide range of blood cancers — from highly curable Hodgkin lymphoma in young adults to the many subtypes of Non-Hodgkin lymphoma (NHL) including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and others. Insurance assessment for lymphoma depends heavily on the specific type, treatment history, and current status.

Hodgkin Lymphoma

Hodgkin lymphoma (HL) is one of the most curable cancers in medicine, with overall survival rates exceeding 85–90% in early stages. Many young New Zealanders are treated for HL with ABVD chemotherapy or BEACOPP and achieve long-term remission. Once in confirmed remission, most travel insurers can offer cover with an additional premium — particularly if 1–2+ years post-treatment.

Non-Hodgkin Lymphoma

NHL is more heterogeneous. DLBCL (the most common aggressive NHL) is treated with R-CHOP chemotherapy and many patients achieve long-term remission. Follicular lymphoma is generally indolent and often managed with "watch and wait" or maintenance rituximab. Mantle cell and T-cell lymphomas are more complex.

For travel insurance purposes, the key questions are the same regardless of NHL subtype: current treatment status, time since last treatment, and evidence of recurrence.

Immunocompromise and Infection Risk

Lymphoma and its treatment significantly suppress the immune system. Chemotherapy (particularly with regimens like R-CHOP or ABVD), corticosteroids, and rituximab all reduce white blood cell counts and immune function.

This has direct implications for travel:

• Neutropenia (low neutrophil count) — travelling with a neutrophil count below 1.0 is generally contraindicated
• High-risk infection destinations — rural Southeast Asia, parts of sub-Saharan Africa, and areas with poor water quality should be avoided during and immediately after chemotherapy
• Vaccinations — live vaccines (yellow fever, oral typhoid) cannot be given to immunocompromised travellers. Some destinations require proof of yellow fever vaccination for entry — check before booking
• Food safety — follow strict food hygiene: cooked food only, bottled water, avoid raw salads and street food at high-risk destinations

CAR-T Cell Therapy and Stem Cell Transplant

Patients who have undergone CAR-T cell therapy or autologous/allogeneic stem cell transplant face the most significant travel restrictions. Post-transplant patients are typically advised to avoid travel for a minimum of 3–6 months (autologous) or 6–12+ months (allogeneic). During this period, the immune system is rebuilding and infection risk is very high.

Insurance for travel post-stem cell transplant will require specific assessment — declare this clearly when applying.

Maintenance Rituximab

Many follicular lymphoma patients receive maintenance rituximab infusions every 2 months. This is manageable for travel, but: plan your travel around infusion dates, ensure supply is available if overseas, and note that rituximab causes B-cell depletion which increases infection susceptibility.

Key Takeaway

For lymphoma patients in confirmed remission — particularly Hodgkin lymphoma survivors — travel insurance is generally accessible with an additional premium. For those in active treatment or recently post-transplant, get haematologist clearance first, then approach insurers with full documentation.